

# Table of Contents

---

<b>Hyman, Phelps &amp; McNamara, P.C.</b> .....	v
<b>About the Editors</b> .....	vii
<b>About the Contributors</b> .....	ix
<b>Table of Chapters</b> .....	xxi
<b>Preface</b> .....	lv

## **Chapter 1     FDA Administrative Actions**

*James P. Ellison & Anne K. Walsh*

§ 1:1	Overview .....	1-3
§ 1:2	FDA's Administrative Authority .....	1-3
§ 1:2.1	Generally .....	1-3
§ 1:2.2	Jurisdiction Granted to FDA Under the FDC Act.....	1-4
§ 1:2.3	FDA's Shared Authority with Other Agencies .....	1-5
[A]	Generally .....	1-5
[B]	U.S. Department of Health and Human Services.....	1-5
[B][1]	Centers for Medicare and Medicaid Services .....	1-6
[C]	U.S. Department of Justice .....	1-6
[C][1]	Consumer Protection Branch .....	1-6
[C][2]	U.S. Attorneys.....	1-7
[C][3]	Drug Enforcement Administration.....	1-7
[D]	Federal Trade Commission .....	1-7
[E]	U.S. Department of Agriculture.....	1-7
[F]	Environmental Protection Agency.....	1-7
[G]	U.S. Patent and Trade Office.....	1-8
[H]	States .....	1-8
[I]	International MOUs.....	1-8
§ 1:3	What Triggers an Administrative Action? .....	1-8
§ 1:3.1	Generally .....	1-8
§ 1:3.2	Types of FDA Action.....	1-9
§ 1:3.3	Common Acts Leading to Administrative Actions....	1-9
[A]	Label and Labeling Violations .....	1-9
[B]	Product Adulteration and Quality Issues .....	1-10
[C]	Acts by Individuals .....	1-10

§ 1:4	Types of Administrative Actions .....	1-11
§ 1:4.1	Inspections .....	1-11
[A]	Generally .....	1-11
[B]	Form 483s .....	1-11
[C]	Examples .....	1-12
Table 1-1	FDA Form 483 Observations .....	1-12
§ 1:4.2	Warning and Untitled Letters .....	1-13
[A]	Generally .....	1-13
[A][1]	Warning Letters .....	1-13
[A][2]	Untitled Letters .....	1-15
[B]	Effect on Future FDA Action .....	1-15
[B][1]	Interactions with FDA .....	1-15
[B][2]	Reputational Harm .....	1-15
[C]	Common Categories .....	1-15
§ 1:4.3	Recalls .....	1-16
[A]	Generally .....	1-16
[A][1]	Mandatory Versus Permissive .....	1-16
[B]	Effect on Future Acts .....	1-17
[B][1]	Interactions with FDA .....	1-17
[B][2]	Reputational Harm .....	1-17
[C]	Examples .....	1-17
[C][1]	Food .....	1-17
[C][2]	Drugs: Compounded Drugs .....	1-18
§ 1:4.4	Import Detentions .....	1-18
[A]	Generally .....	1-18
[B]	OASIS System .....	1-18
[C]	Effect on Future FDA Action .....	1-19
[C][1]	Interactions with FDA .....	1-19
[C][2]	Reputational Harm .....	1-19
[D]	Examples .....	1-19
§ 1:4.5	Administrative Detentions .....	1-19
[A]	Generally .....	1-19
[A][1]	Food .....	1-19
[A][2]	Devices .....	1-20
[A][3]	Drugs .....	1-20
[B]	Effect on Future FDA Action .....	1-20
[C]	Examples .....	1-20
§ 1:4.6	Clinical Holds .....	1-21
[A]	Generally .....	1-21
[B]	Effect on Future FDA Action .....	1-21
[C]	Examples .....	1-21
§ 1:4.7	Application Integrity Policy .....	1-22
[A]	Generally .....	1-22
[B]	Effect on Future FDA Action .....	1-22

*Table of Contents*

§ 1:4.8	Civil Monetary Penalties.....	1-22
[A]	Generally .....	1-22
[B]	Effect on Future Acts .....	1-22
[C]	Examples .....	1-23
§ 1:4.9	Disqualification of Clinical Investigators .....	1-23
[A]	Generally .....	1-23
[B]	Effect on Future Acts .....	1-23
[C]	Examples .....	1-23
§ 1:4.10	Debarment.....	1-24
[A]	Generally .....	1-24
[A][1]	Individuals Versus Corporate Entities.....	1-24
[A][2]	Mandatory Versus Permissive.....	1-24
[A][3]	Difference from Disqualification .....	1-25
[B]	Effect on Future Acts .....	1-25
[B][1]	Temporary Versus Permanent.....	1-25
[B][2]	Potential for Termination .....	1-25
[C]	Examples .....	1-25
§ 1:4.11	Publicity.....	1-26
[A]	Generally .....	1-26
[B]	Effect on Future Acts .....	1-26
§ 1:5	Frequency of Administrative Actions .....	1-26
§ 1:5.1	Commonly Used Actions.....	1-26
[A]	Warning and Untitled Letters .....	1-26
[B]	Recalls .....	1-26
[C]	Import Detentions .....	1-26
§ 1:5.2	Less Common Actions.....	1-27
§ 1:6	Facing Administrative Actions.....	1-27
§ 1:6.1	What to Do.....	1-27
§ 1:6.2	What NOT to Do .....	1-27
§ 1:6.3	Avoiding Administrative Action.....	1-27

**Chapter 2     FDA Civil Enforcement Actions**

*Robert A. Dormer, Anne K. Walsh & Kalie E. Richardson*

§ 2:1	Overview .....	2-2
§ 2:2	Relevant Government Actors.....	2-2
§ 2:2.1	FDA Offices .....	2-2
[A]	Office of Regulatory Affairs .....	2-2
[B]	Centers' Office of Compliance .....	2-3
[C]	Office of the Chief Counsel .....	2-4
§ 2:2.2	U.S. Department of Justice .....	2-4
[A]	Civil Division, Consumer Protection Branch.....	2-4
[B]	U.S. Attorneys' Offices .....	2-5

§ 2:3	Guidelines for Taking Enforcement Action .....	2-6
§ 2:3.1	Regulatory Procedures Manual .....	2-6
§ 2:3.2	Compliance Policy Guides .....	2-6
§ 2:3.3	Enforcement Discretion .....	2-7
§ 2:3.4	DOJ Enforcement Policy .....	2-9
§ 2:4	Seizures .....	2-11
§ 2:4.1	Overview .....	2-11
§ 2:4.2	Legal Authority .....	2-12
§ 2:4.3	What Products Can Be Seized? .....	2-12
§ 2:4.4	Procedures .....	2-14
[A]	Judicial Procedure .....	2-14
[B]	Coordination with U.S. Marshals Service .....	2-15
[C]	Disposition of Seized Product .....	2-15
§ 2:4.5	Challenging a Seizure Action .....	2-16
§ 2:5	Injunctions .....	2-17
§ 2:5.1	Overview .....	2-17
§ 2:5.2	Legal Authority .....	2-17
[A]	Overview .....	2-17
[B]	Types of Injunctions .....	2-18
[B][1]	Temporary Restraining Order .....	2-18
[B][2]	Preliminary Injunction .....	2-18
[B][3]	Permanent Injunction .....	2-19
[C]	Factors Considered by FDA .....	2-19
§ 2:5.3	Procedures for Initiating an Injunction Action .....	2-20
[A]	Initial Decision .....	2-20
[B]	Review by Office of the Chief Counsel .....	2-21
[C]	Referral to Department of Justice .....	2-21
§ 2:5.4	Defending Against an Injunction Action .....	2-22
§ 2:5.5	Consent Decree Provisions .....	2-22
§ 2:5.6	Vacating an Injunction .....	2-25
§ 2:6	Equitable Remedies: Restitution and Disgorgement .....	2-26

### **Chapter 3     FDA Criminal Enforcement Actions**

*James P. Ellison*

§ 3:1	Overview .....	3-2
§ 3:2	FDC Act Violations .....	3-3
§ 3:2.1	Section 301 Prohibited Acts As the Basis for Criminal Violations .....	3-3
[A]	Generally .....	3-3
[B]	FDA Regulations As the Basis for a Criminal Charge .....	3-3
§ 3:2.2	FDC Act Strict Liability Criminal Violations .....	3-4
[A]	Regulated Persons and Entities .....	3-4

*Table of Contents*

[B]	Responsible Corporate Officers .....	3-4
[B][1]	Generally.....	3-4
[B][2]	Precedent of <i>Dotterweich</i> and <i>Park</i> .....	3-5
[B][3]	Impossibility Defense.....	3-7
§ 3:2.3	Felony Violations of the FDC Act .....	3-8
[A]	Generally .....	3-8
[B]	“Second” Offenses .....	3-9
[B][1]	Generally.....	3-9
[B][2]	It Is Only a Second Offense If the Government Charges It As Such .....	3-9
[C]	Intent to Defraud or Mislead FDA or Consumers .....	3-10
§ 3:2.4	Other Title 21 Criminal Violations.....	3-10
§ 3:2.5	FDC Act Criminal Penalties .....	3-11
[A]	Terms of Imprisonment.....	3-11
[B]	Fines .....	3-11
[B][1]	Generally.....	3-11
[B][2]	Alternative Fine Provision of 18 U.S.C. § 3571(d) .....	3-12
§ 3:2.6	Title 21 Statute of Limitations.....	3-12
§ 3:3	Title 18 Alternatives to FDC Act Charges .....	3-13
§ 3:3.1	Alternative Criminal Statutes .....	3-13
[A]	Mail Fraud Act, 18 U.S.C. § 1341.....	3-13
[B]	Wire Fraud Act, 18 U.S.C. § 1343 .....	3-13
[C]	Criminal Conspiracy Statute, 18 U.S.C. § 371 .....	3-13
[D]	Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. §§ 1961–1968 .....	3-13
[E]	Health Care Fraud, 18 U.S.C. § 1347 .....	3-14
[F]	False Statements, 18 U.S.C. § 1001 .....	3-14
[G]	Obstruction of Proceedings Before Agencies, 18 U.S.C. § 1505 .....	3-14
§ 3:3.2	Longer Statutory Maximum Terms of Imprisonment.....	3-14
§ 3:3.3	Simpler Jury Instructions.....	3-15
§ 3:3.4	Statute of Limitations .....	3-15
§ 3:4	Prosecutors .....	3-15
§ 3:4.1	U.S. Attorneys .....	3-15
§ 3:4.2	Consumer Protection Branch.....	3-15
§ 3:4.3	FDA Office of the Chief Counsel .....	3-16
§ 3:5	Jurisdictional Considerations.....	3-16
§ 3:5.1	Where Can an FDA Case Be Brought? .....	3-16
§ 3:5.2	Extra-Territorial Application .....	3-16
§ 3:5.3	Extradition.....	3-16

§ 3:6 Current Trends in Criminal Prosecution:  
*Qui Tams* and Parallel Proceedings ..... 3-17  
 § 3:6.1 Generally ..... 3-17  
 § 3:7 Sentencing Guidelines ..... 3-17

**Chapter 4 Other Authorities Governing FDA-Regulated Entities**

*Michelle L. Butler, Larry K. Houck,  
 Alan M. Kirschenbaum, Riëtte van Laack &  
 Ricardo Carvajal*

§ 4:1 Overview ..... 4-2  
 § 4:2 FTC Regulation of Advertising for FDA-Regulated  
 Products ..... 4-3  
 § 4:2.1 Generally ..... 4-3  
 § 4:2.2 Labeling and Advertising of Over-the-Counter  
 Products ..... 4-3  
     [A] Substantiation of Advertising Claims ..... 4-3  
     [B] FTC Investigative and Enforcement Tools ..... 4-5  
         [B][1] Generally ..... 4-5  
         [B][2] Enforcement Actions ..... 4-6  
 § 4:2.3 “Made in the U.S.A.” ..... 4-9  
 § 4:2.4 Overlap with Self-Regulatory Bodies—National  
 Advertising Division, Electronic Retailing  
 Self-Regulation Program, and Children’s  
 Advertising Review Unit ..... 4-12  
 § 4:3 Drug Enforcement Administration ..... 4-13  
 § 4:4 U.S. Department of Agriculture: Plant and Animal  
 Pests, Animal Welfare, and Biotechnology ..... 4-15  
     § 4:4.1 Generally ..... 4-15  
     § 4:4.2 Imports and Permits ..... 4-16  
     § 4:4.3 Animal Welfare ..... 4-17  
     § 4:4.4 Biotechnology ..... 4-18  
 § 4:5 Agencies Administering Certain Health Care and  
 Price Reporting Laws ..... 4-19  
     § 4:5.1 Generally ..... 4-19  
     § 4:5.2 Health Care Fraud and Abuse Laws ..... 4-20  
     § 4:5.3 Government Price Reporting and Government  
     Drug Discount Programs ..... 4-20  
         [A] Medicaid Drug Rebate Program ..... 4-20  
         [B] 340B Drug Discount Program ..... 4-22  
         [C] Medicare Part B and Average Sales Price ..... 4-23  
         [D] Medicare Part D and the Coverage Gap  
         Discount Program ..... 4-24

Table of Contents

[E]	Federal Supply Schedule Contracts .....	4-24
[F]	TRICARE Retail Pharmacy Network Program .....	4-26
§ 4:5.4	Branded Pharmaceutical Fee .....	4-27
§ 4:6	Customs and Border Protection .....	4-27
§ 4:6.1	Generally .....	4-27
§ 4:6.2	Import Inspections.....	4-27
§ 4:6.3	Country of Origin Labeling.....	4-29
§ 4:7	State Attorneys General.....	4-30
§ 4:7.1	Generally .....	4-30
§ 4:7.2	State Food, Drug, and Cosmetic Acts.....	4-30
§ 4:7.3	State Consumer Protection Acts and Unfair Competition Laws .....	4-31
§ 4:7.4	State False Claims Acts.....	4-32
§ 4:7.5	State Slack-Fill Regulations.....	4-33
§ 4:7.6	California Proposition 65.....	4-34
§ 4:8	International Regulatory Bodies.....	4-35
§ 4:8.1	World Health Organization/Food and Agriculture Organization, Codex Alimentarius Commission—International Food Standards .....	4-35
§ 4:8.2	WHO—Drug Prequalification .....	4-36
§ 4:9	Product Liability .....	4-36

**Chapter 5 Over-the-Counter Drugs**

*Paul M. Hyman, Riëtte van Laack &  
Deborah L. Livornese*

§ 5:1	Introduction .....	5-2
§ 5:2	Definition of Over-the-Counter Drugs .....	5-3
§ 5:3	OTC Drugs Marketed Under a Monograph.....	5-4
§ 5:3.1	Generally .....	5-4
§ 5:3.2	OTC Drug Review Process.....	5-5
[A]	Original OTC Drug Review .....	5-5
[B]	OTC Monograph Reform.....	5-8
[B][1]	Reform of the OTC Monograph Drug Review Process .....	5-8
[B][1][a]	Revised Status of Drugs Currently Covered by the OTC Drug Review.....	5-8
[B][1][b]	New Administrative Orders .....	5-9
[B][1][b][i]	Proposed Ordinary Orders Issued on FDA's Initiative .....	5-9
[B][1][b][ii]	Imminent Hazard Orders and Safety Labeling Changes .....	5-10
[B][1][b][iii]	Orders Initiated on Request.....	5-10

	[B][1][c]	Exclusivity.....	5-11
	[B][1][d]	Appeals and Hearings Related to Final Orders .....	5-11
	[B][1][e]	Minor Changes in Dosage Form.....	5-12
	[B][2]	User Fees; the OTC Monograph User Fee Act ....	5-12
	[B][2][a]	Facility Fees.....	5-12
	[B][2][b]	Order Fees .....	5-13
	[B][2][c]	Timing/FDA Goals Letter.....	5-13
§ 5:3.3		General OTC Drug Labeling Requirements .....	5-14
§ 5:3.4		Monograph Requirements.....	5-15
	[A]	Generally .....	5-15
	[B]	Active Ingredients .....	5-15
	[C]	Indications.....	5-17
	[D]	Dosage Strength and Route of Administration .....	5-18
	[E]	Warnings and Directions .....	5-18
	[F]	Formulation Testing.....	5-19
	[G]	Claims .....	5-19
§ 5:3.5		Sunscreen Innovation Act.....	5-19
§ 5:4		FDA Enforcement of Monograph Requirements .....	5-22
	§ 5:4.1	Generally .....	5-22
	§ 5:4.2	Inspections .....	5-22
	§ 5:4.3	Warning Letters.....	5-23
	§ 5:4.4	Additional Enforcement Actions .....	5-24
§ 5:5		Other Paths to Market .....	5-25
	§ 5:5.1	Generally .....	5-25
	§ 5:5.2	Direct-to-OTC NDA .....	5-25
	§ 5:5.3	NDA Deviation.....	5-26
	§ 5:5.4	NDA Supplement .....	5-26
	§ 5:5.5	505(b)(2) NDA.....	5-27
	§ 5:5.6	Homeopathic Drugs.....	5-27
	§ 5:5.7	Unapproved Drugs.....	5-29
§ 5:6		Entities Responsible for Enforcement .....	5-29
	§ 5:6.1	FDA.....	5-29
	§ 5:6.2	U.S. Department of Justice .....	5-30
	§ 5:6.3	Federal Trade Commission .....	5-30
	§ 5:6.4	Others.....	5-31

## **Chapter 6      Drugs: Current Good Manufacturing Practice**

*Mark I. Schwartz & Douglas B. Farquhar*

§ 6:1	Introduction .....	6-2
§ 6:2	GMPs Versus cGMPs.....	6-4
§ 6:3	FDA's Risk-Based Approach to Its Statutory Mandate .....	6-5



*Table of Contents*

§ 6:4	Scope of cGMPs .....	6-6
§ 6:4.1	Introduction.....	6-6
§ 6:4.2	Drug Substance Versus Drug Product .....	6-6
§ 6:4.3	Investigational Drug Products.....	6-7
§ 6:4.4	Excipients .....	6-9
§ 6:4.5	For Export Only .....	6-9
§ 6:5	General Principles of cGMPs .....	6-10
§ 6:5.1	Introduction.....	6-10
§ 6:5.2	Quality Management System—The Foundation for Compliance .....	6-10
[A]	Introduction .....	6-10
[B]	Management Oversight and Review.....	6-11
[C]	The Quality Unit.....	6-12
[D]	Quality System Development and Implementation.....	6-13
[E]	Training and Education.....	6-14
[F]	Quality Metrics.....	6-15
§ 6:5.3	Control Over Process .....	6-17
[A]	Generally .....	6-17
[B]	Process Understanding .....	6-17
[C]	In-Process Controls .....	6-18
[D]	Process Validation .....	6-18
§ 6:5.4	Control Over Materials.....	6-19
[A]	Generally .....	6-19
[B]	Vendor Controls.....	6-20
[C]	Raw Materials.....	6-21
[D]	Manufacturing Equipment.....	6-21
[E]	Packaging.....	6-21
[E][1]	Generally.....	6-21
[E][2]	Container and Closure Systems .....	6-22
[E][3]	Outer Packaging and Labeling .....	6-22
§ 6:5.5	Control Over Product.....	6-23
[A]	Generally .....	6-23
[B]	Laboratory Testing and Product Release .....	6-23
[C]	Shipment and Distribution.....	6-23
[D]	Stability Testing .....	6-24
§ 6:5.6	Control Over Records .....	6-24
[A]	Generally .....	6-24
[B]	Recordkeeping.....	6-24
[C]	Record Retention .....	6-25
[D]	Data Integrity .....	6-25
§ 6:5.7	Control Over the Unexpected .....	6-27
[A]	Generally .....	6-27
[B]	Deviations .....	6-27
[C]	Out of Specification Results.....	6-27

	[D]	Complaints.....	6-28
	[E]	Investigations .....	6-28
	[F]	Corrective and Preventive Actions .....	6-28
§ 6:6		Putting the “c” in cGMPs .....	6-29
	§ 6:6.1	Introduction.....	6-29
	§ 6:6.2	Routine Internal Auditing.....	6-29
	§ 6:6.3	Review of Procedures and Protocols .....	6-30
	§ 6:6.4	Maintaining Industry Awareness .....	6-30
		[A] Generally .....	6-30
		[B] Sources of Best Practices .....	6-30
		[B][1] FDA Inspections and Warning Letters .....	6-30
		[B][2] FDA Guidance .....	6-30
		[B][3] USP and Other Compendia.....	6-30
		[B][4] ICH.....	6-31
		[C] Keeping Up with Technology .....	6-31
§ 6:7		Enforcement and Penalties .....	6-31
	§ 6:7.1	Pre-Approval and Routine Facility Inspections .....	6-31
	§ 6:7.2	Impact on Pending or Future Submissions.....	6-32
	§ 6:7.3	Enforcement Trends.....	6-33

## **Chapter 7 Drug Compounding**

*Karla L. Palmer & Jeffrey N. Gibbs*

§ 7:1		Pharmaceutical Compounding: Well-Recognized and Critically Important.....	7-2
§ 7:2		Food and Drug Administration Modernization Act and its Tortured Constitutional History: Federal Courts Divide Over Compounding.....	7-3
§ 7:3		New England Compounding Center and 2013 Congressional Action.....	7-5
§ 7:4		Passage of the Drug Quality and Security Act, Title I (the Compounding Quality Act) .....	7-8
	§ 7:4.1	Generally .....	7-8
	§ 7:4.2	Reinstated Section 503A; Reinvigorated FDA .....	7-9
		[A] Generally.....	7-9
		[B] FDA's Guidance Addressing Section 503A.....	7-15
		[C] FDA's Draft Memorandum of Understanding with States on Interstate Shipments of Compounded Products .....	7-19
	§ 7:4.3	Section 503B: Outsourcing Facilities.....	7-22
		[A] Generally .....	7-22
		[B] General Section 503B Requirements: Registration, Reporting, cGMP, and FDA Inspections.....	7-23

*Table of Contents*

[C]	Outsourcing Facility Restrictions on Compounding.....	7-26
[C][1]	Generally .....	7-26
[C][2]	Compounding of Products on FDA's Published Shortage List .....	7-27
[C][3]	FDA's Section 503B Positive List.....	7-27
[C][4]	Withdrawn Drugs, the Negative List, and "Essentially Copies" .....	7-30
[C][5]	Prohibition on Wholesaling and Transfers.....	7-31
[C][6]	FDA's "Facility" Definition for Section 503B Outsourcing Facilities.....	7-31
§ 7:4.4	FDA's Pharmacy Compounding Advisory Committee .....	7-32
[A]	Generally .....	7-32
[B]	Committee Membership.....	7-33
§ 7:5	Conclusion .....	7-33

**Chapter 8 Clinical Trials**

*David B. Clissold & James E. Valentine*

§ 8:1	Federal Regulation of Clinical Trials .....	8-3
§ 8:1.1	History and Overview .....	8-3
§ 8:1.2	U.S. Department of Health and Human Services: Policy for Protection of Human Research Subjects (the "Common Rule") .....	8-4
§ 8:1.3	FDA Regulations Regarding the Protection of Human Research Subjects.....	8-5
§ 8:2	FDA Regulations for Clinical Studies of Investigational Drugs and Devices.....	8-6
§ 8:2.1	Regulated Entities .....	8-6
§ 8:2.2	Sponsors .....	8-7
[A]	General Responsibilities .....	8-7
[B]	Requirements for an Investigational New Drug Application or Investigational Device Exemption.....	8-8
[B][1]	INDs .....	8-8
[B][2]	IDEs .....	8-10
[C]	Selecting Investigators and Monitors .....	8-13
[D]	Obtaining Information from Investigators .....	8-14
[D][1]	Generally .....	8-14
[D][2]	Selecting Monitors .....	8-16
[D][3]	Informing Investigators.....	8-17
[E]	Review of Ongoing Clinical Investigations.....	8-18
[F]	Recordkeeping and Retention.....	8-20

	[G]	Disposition of Unused Investigational Products.....	8-20
	[H]	CROs.....	8-21
§ 8:2.3		Investigators .....	8-21
	[A]	General Responsibilities .....	8-21
	[B]	Control of Investigational Products .....	8-22
	[C]	Recordkeeping and Retention.....	8-22
	[D]	Investigator Reporting Requirements .....	8-22
	[E]	Obtaining Informed Consent.....	8-24
	[E][1]	Generally .....	8-24
	[E][2]	Required Elements of Informed Consent .....	8-25
	[E][3]	Additional Elements .....	8-30
	[F]	Assurance of IRB Review .....	8-32
§ 8:2.4		Institutional Review Boards .....	8-33
	[A]	Scope .....	8-33
	[B]	Organization.....	8-34
	[C]	Functions and Operations.....	8-35
	[D]	Additional Protections: Vulnerable Populations.....	8-38
§ 8:2.5		Clinical Holds and Staged Approval.....	8-42
	[A]	Generally .....	8-42
	[B]	Grounds for Imposition of Clinical Hold .....	8-43
	[C]	Process for Imposition of Clinical Hold .....	8-45
	[D]	Resumption of Clinical Investigations .....	8-46
§ 8:2.6		IND/IDE Termination.....	8-46
§ 8:2.7		IND/IDE Withdrawal.....	8-47
§ 8:3		Clinical Trial Registration and Results Submission.....	8-47
§ 8:3.1		Regulatory History .....	8-47
§ 8:3.2		Applicable Clinical Trials .....	8-49
§ 8:3.3		Responsible Party .....	8-50
§ 8:3.4		Registration.....	8-51
§ 8:3.5		Results Reporting of Completed Trials .....	8-52
§ 8:3.6		ClinicalTrials.gov Compliance .....	8-55
§ 8:4		Potential Conflicts of Interest and Financial Disclosure Regulations .....	8-56
§ 8:5		Postmarketing Studies .....	8-60
§ 8:5.1		Postmarketing Commitments and Requirements for Drugs.....	8-60
§ 8:5.2		Post-Approval Studies for Devices.....	8-61
§ 8:5.3		Confirmatory Studies for Accelerated Drug Approvals.....	8-63
§ 8:5.4		Postmarketing Requirements for Drugs Approved Under the Animal Rule.....	8-64
§ 8:5.5		Pediatric Postmarketing Studies .....	8-65

*Table of Contents*

§ 8:6 FDA Inspections and Enforcement Mechanisms ..... 8-65

    § 8:6.1 Bioresearch Monitoring Program ..... 8-65

        [A] FDA Inspections of Sponsors and CROs..... 8-66

        [B] FDA Inspections of Clinical Investigators..... 8-67

        [C] FDA Inspections of Institutional Review Boards ..... 8-68

        [D] Upon Conclusion of an FDA Inspection..... 8-69

    § 8:6.2 FDA Enforcement Under BIMO ..... 8-69

        [A] Issuing Untitled, Warning, and  
Restrictions Letters ..... 8-70

        [B] Investigator Disqualification..... 8-70

        [C] Debarment ..... 8-73

    § 8:6.3 FDA Inspections and Enforcement ..... 8-73

        [A] Clinical Investigators ..... 8-73

        [B] Sponsors and CROs ..... 8-74

        [C] IRBs ..... 8-74

Appendix 8A Statement of Investigator, Form  
FDA 1572 ..... App. 8A-1

**Chapter 9 Quality System Regulation**

*Jeffrey K. Shapiro & Allyson B. Mullen*

§ 9:1 Overview ..... 9-2

§ 9:2 General Provisions..... 9-3

    § 9:2.1 Overview..... 9-3

    § 9:2.2 Scope ..... 9-3

        [A] History and Authority..... 9-3

        [B] Applicability ..... 9-4

        [B][1] Generally ..... 9-4

        [B][2] Foreign Manufacturers ..... 9-5

        [C] Exemptions..... 9-5

    § 9:2.3 Definitions..... 9-5

§ 9:3 Quality System Requirement ..... 9-7

    § 9:3.1 Generally ..... 9-7

    § 9:3.2 Quality System ..... 9-7

    § 9:3.3 Management Responsibility..... 9-8

        [A] Management with Executive Responsibility..... 9-8

        [B] Quality Policy ..... 9-8

        [C] Organization and Resources..... 9-9

        [C][1] Generally ..... 9-9

        [C][2] Organization ..... 9-9

        [C][3] Resources ..... 9-9

        [D] Responsibility and Authority ..... 9-10

        [E] Management Representative..... 9-10

[F]	Management Review.....	9-11
[G]	Quality Planning.....	9-12
[H]	Quality System Procedures .....	9-12
§ 9:3.4	Quality Audits .....	9-13
§ 9:3.5	Personnel .....	9-14
[A]	Generally .....	9-14
[B]	Training.....	9-14
§ 9:4	Design Controls .....	9-15
§ 9:4.1	Design Control Requirements.....	9-15
[A]	Generally .....	9-15
[B]	Applicability .....	9-15
[C]	Design and Development Planning.....	9-16
[D]	Design Inputs and Outputs .....	9-16
[E]	Design Review .....	9-17
[F]	Design Verification .....	9-18
[G]	Design Validation.....	9-18
[H]	Design Transfer.....	9-19
[I]	Design Changes.....	9-19
[J]	Design History File, Device Master Record, and Device History Record .....	9-19
§ 9:5	Purchasing Controls .....	9-20
§ 9:6	Production and Process Controls .....	9-21
§ 9:6.1	Production and Process Control Requirements .....	9-21
§ 9:6.2	Inspection, Measuring, and Test Equipment .....	9-22
§ 9:6.3	Process Validation .....	9-22
§ 9:7	Control of Devices .....	9-23
§ 9:7.1	Receiving, In-Process, and Finished Device Acceptance.....	9-23
§ 9:7.2	Acceptance Status and Identification .....	9-24
§ 9:7.3	Nonconforming Product .....	9-24
§ 9:8	Corrective and Preventive Action.....	9-25
§ 9:9	Labeling and Traceability .....	9-26
§ 9:9.1	Labeling Control .....	9-26
§ 9:9.2	Traceability .....	9-26
§ 9:10	Records.....	9-27
§ 9:10.1	General Requirements .....	9-27
§ 9:10.2	Document Controls and Good Documentation Practices.....	9-27
§ 9:11	Complaint Handling.....	9-28
§ 9:12	Servicing.....	9-29

**Chapter 10 Devices: Recalls**

*Jeffrey K. Shapiro & Allyson B. Mullen*

§ 10:1	Overview .....	10-2
§ 10:2	General Provisions.....	10-2
§ 10:2.1	Scope .....	10-2
§ 10:2.2	Definitions.....	10-3
[A]	Correction .....	10-3
[B]	Removal.....	10-3
[C]	Market Withdrawal.....	10-3
[D]	Risk to Health .....	10-3
[E]	Routine Servicing.....	10-4
[F]	Stock Recovery.....	10-4
§ 10:2.3	Types of Recalls.....	10-4
[A]	Firm-Initiated Recall.....	10-4
[B]	FDA-Requested Recall.....	10-5
[C]	FDA Mandatory Recall Authority .....	10-6
§ 10:3	Identification and Classification .....	10-6
§ 10:3.1	Identifying Potential Recalls.....	10-6
§ 10:3.2	Health Risk Assessment/Health Hazard Evaluation.....	10-7
§ 10:3.3	Classification .....	10-8
§ 10:4	Recall Execution .....	10-8
§ 10:4.1	Strategy.....	10-8
[A]	Generally .....	10-8
[B]	Elements of a Recall Strategy .....	10-8
[B][1]	Depth of Recall .....	10-8
[B][2]	Public Warning.....	10-9
[B][3]	Effectiveness Checks .....	10-9
§ 10:4.2	Communication .....	10-9
[A]	Consignee Communication .....	10-9
[B]	Public Notification.....	10-10
§ 10:4.3	Recall Status Reports .....	10-10
§ 10:4.4	Termination.....	10-11
§ 10:5	Reporting to FDA.....	10-11
§ 10:5.1	Scope .....	10-11
[A]	Applicability .....	10-11
[B]	Exemptions.....	10-12
§ 10:5.2	Initial Reports .....	10-14
§ 10:5.3	Status Reports.....	10-16
§ 10:6	Recordkeeping.....	10-16
§ 10:6.1	Recall Records.....	10-16
§ 10:6.2	Access to Recall Records .....	10-16
Appendix 10A	Form Template HHE.....	App. 10A-1
Appendix 10B	Recall Notification Letter .....	App. 10B-1

**Chapter 11 Devices: Medical Device Reports**

*Jeffrey K. Shapiro & Allyson B. Mullen*

§ 11:1 Overview ..... 11-2

§ 11:2 General Provisions..... 11-2

    § 11:2.1 Scope ..... 11-2

        [A] Authority ..... 11-2

        [B] Applicability of MDR Requirements to Regulated Industries ..... 11-3

            [B][1] Manufacturer ..... 11-3

            [B][2] Importer..... 11-4

            [B][3] User Facility..... 11-4

        [C] Exemptions, Variances, and Alternative Reporting ..... 11-5

    § 11:2.2 General Provisions ..... 11-6

        [A] Public Disclosure of MDRs..... 11-6

        [B] MDRs Not an Admission ..... 11-6

§ 11:3 Reportable Events ..... 11-7

    § 11:3.1 Death or Serious Injury..... 11-8

    § 11:3.2 Malfunction ..... 11-9

    § 11:3.3 Foreign Events ..... 11-11

§ 11:4 Procedures and Record..... 11-12

    § 11:4.1 MDR Procedure Requirements..... 11-12

        [A] General Requirements ..... 11-12

        [B] Identification of Reportable Events ..... 11-13

            [B][1] Device-Related Complaint Review ..... 11-13

            [B][2] Receipt of Voluntary Reports ..... 11-13

    § 11:4.2 MDR Files ..... 11-13

§ 11:5 Reporting..... 11-14

    § 11:5.1 How to Report ..... 11-14

    § 11:5.2 MDR Required Information..... 11-16

        [A] General Requirements ..... 11-16

        [B] Reporting Codes ..... 11-16

        [C] Multiple Devices..... 11-17

§ 11:6 Manufacturer Requirements ..... 11-17

    § 11:6.1 Reporting Requirements..... 11-17

        [A] Thirty-Day Reports..... 11-17

        [B] Five-Day Reports ..... 11-17

    § 11:6.2 Supplemental Reports ..... 11-18

    § 11:6.3 Foreign Manufacturers ..... 11-18

    § 11:6.4 Voluntary Malfunction Summary Reporting Program ..... 11-18



Table of Contents

§ 11:7	Importer Requirements.....	11-19
§ 11:8	User Facility Requirements.....	11-19
§ 11:8.1	Individual Reports.....	11-19
§ 11:8.2	Annual Reports.....	11-20
§ 11:9	Distributor Requirements.....	11-20

**Chapter 12 Devices: *In Vitro* Diagnostic Devices**

Jeffrey N. Gibbs & Serra J. Schlanger

§ 12:1	Overview .....	12-2
§ 12:2	Definition of <i>In Vitro</i> Diagnostics (IVDs).....	12-2
§ 12:2.1	Statutory Definition: FDC Act § 201(h).....	12-2
§ 12:2.2	Regulation: 21 C.F.R. § 809.3 .....	12-3
§ 12:2.3	Courts Broadly Interpret “Diagnose”.....	12-3
§ 12:3	Overlap with Other Device Regulatory Provisions .....	12-6
§ 12:3.1	Office of <i>In Vitro</i> Diagnostics and Radiological Health.....	12-6
§ 12:3.2	Classification Scheme.....	12-6
§ 12:3.3	Importance of Intended Use.....	12-7
§ 12:3.4	Premarket Review .....	12-8
§ 12:3.5	Quality System Regulation.....	12-9
§ 12:3.6	Recalls, Corrections and Removals .....	12-9
§ 12:3.7	Registration and Listing .....	12-10
§ 12:3.8	Medical Device Reporting.....	12-10
§ 12:3.9	Labeling/Promotion.....	12-10
§ 12:4	Laboratory-Developed Tests .....	12-11
§ 12:4.1	Generally .....	12-11
§ 12:4.2	Clinical Laboratory Improvement Amendments of 1988 .....	12-11
§ 12:4.3	FDA Asserts Authority Over LDTs.....	12-11
§ 12:4.4	1997 Analyte Specific Reagents Regulation.....	12-12
§ 12:4.5	Warning Letters.....	12-13
§ 12:4.6	Active FDA Risk-Based Approach Regulation of LDTs.....	12-16
§ 12:4.7	“It Has Come to Our Attention” Letters .....	12-16
§ 12:4.8	FDA Draft Guidance on the Active Regulation of LDTs.....	12-20
§ 12:4.9	LDT Draft Guidances: Support and Opposition.....	12-21
§ 12:5	Analyte Specific Reagents .....	12-23
§ 12:5.1	Definition.....	12-23
§ 12:5.2	ASR Distribution Limitations .....	12-24
§ 12:5.3	September 2007 FDA Guidance Narrows Scope of ASRs.....	12-25

§ 12:6	Research Use Only/Investigational Use Only Products.....	12-25
§ 12:6.1	Research Use Only Products .....	12-25
§ 12:6.2	Investigational Use Only Products.....	12-28
§ 12:7	Forensic Use.....	12-29
§ 12:7.1	For Law Enforcement Purposes .....	12-29
§ 12:7.2	Warning Letters.....	12-31
§ 12:8	General Purpose Reagents .....	12-33
§ 12:9	SARS-CoV-2 Testing.....	12-34

## **Chapter 13 Human Food and Dietary Supplements**

*Diane B. McColl, Riëtte van Laack & Ricardo Carvajal*

§ 13:1	Overview .....	13-3
§ 13:2	Foods .....	13-4
§ 13:2.1	Generally .....	13-4
§ 13:2.2	Dietary Supplements .....	13-4
§ 13:2.3	Meat, Poultry, and Egg Products.....	13-5
§ 13:3	Food and Drug Administration.....	13-8
§ 13:3.1	Generally .....	13-8
§ 13:3.2	Adulteration.....	13-9
[A]	Generally .....	13-9
[B]	Unintended Components/Contaminants.....	13-9
[B][1]	Poisonous or Deleterious Substances.....	13-9
[B][2]	Current Good Manufacturing Practice and Hazard Analysis and Critical Control Points.....	13-11
[B][2][a]	Generally.....	13-11
[B][2][b]	Low-Acid Canned Foods and Acidified Foods cGMPs .....	13-12
[B][2][c]	Infant Formula cGMPs.....	13-13
[B][2][d]	Hazard Analysis and Critical Control Points for Juices, and for Fish and Fishery Products.....	13-14
[B][2][e]	Dietary Supplement cGMPs.....	13-15
[B][3]	Food Safety Modernization Act.....	13-16
[C]	Substances Intentionally Added to Food .....	13-19
[C][1]	Generally.....	13-19
[C][2]	Food Additives.....	13-20
[C][2][a]	Generally.....	13-20
[C][2][b]	Food Contact Substances .....	13-20
[C][3]	Color Additives .....	13-21
[C][4]	GRAS Uses of Substances .....	13-22
[C][5]	Pesticides.....	13-23
[C][6]	Dietary Ingredients.....	13-23

*Table of Contents*

§ 13:3.3	Misbranding .....	13-24
[A]	Generally .....	13-24
[B]	Mandatory Label Requirements .....	13-25
[C]	Health Claims .....	13-27
[D]	Nutrient Content Claims .....	13-29
[E]	Structure/Function Claims.....	13-29
[F]	Menu Labeling.....	13-30
[G]	Other Labeling Claims.....	13-31
§ 13:3.4	Miscellaneous Provisions.....	13-31
[A]	Facility Registration .....	13-31
[B]	Distribution and Recordkeeping.....	13-32
[C]	Reportable Food Registry.....	13-32
[D]	Adverse Event Reporting.....	13-33
§ 13:4	FDA Enforcement Powers Related to Foods .....	13-33
§ 13:4.1	Inspections .....	13-33
§ 13:4.2	Recalls .....	13-35
[A]	“Voluntary” Recalls.....	13-35
[B]	Mandatory Recalls .....	13-36
§ 13:4.3	Warning and Other Letters.....	13-37
[A]	Warning Letters .....	13-37
[B]	Cyber Letters .....	13-38
[C]	Courtesy Letters .....	13-38
§ 13:4.4	Suspension of Facility Registration.....	13-38
§ 13:4.5	Administrative Detention .....	13-39
§ 13:4.6	Seizure .....	13-40
§ 13:4.7	Injunction.....	13-41
§ 13:4.8	Criminal Actions .....	13-41
[A]	Strict Liability.....	13-41
[B]	Felonies .....	13-43
§ 13:4.9	Regulatory Compliance Guaranties.....	13-44
§ 13:4.10	Enforcement Actions Related to Import of Foods.....	13-45
[A]	Administrative Holds, Detentions, and Refusals.....	13-45
[B]	Debarment .....	13-47
§ 13:5	Food Safety Inspection Service.....	13-47
§ 13:5.1	Generally .....	13-47
§ 13:5.2	Adulteration.....	13-49
[A]	Generally.....	13-49
[B]	HACCP .....	13-49
[C]	Sanitary, Processing and Facility Requirements for Egg Products Processing.....	13-52
[D]	Ingredients.....	13-52
§ 13:5.3	Misbranding .....	13-53

§ 13:6	FSIS Enforcement .....	13-55
§ 13:6.1	Generally .....	13-55
§ 13:6.2	Inspection-Related Enforcement Powers of FSIS .....	13-56
§ 13:6.3	Actions Against Products .....	13-56
	[A] Generally .....	13-56
	[B] Product Recalls .....	13-57
§ 13:6.4	Administrative Actions .....	13-57
	[A] Rules of Practice.....	13-57
	[B] Regulatory Control Actions.....	13-58
	[C] Suspension of Inspection .....	13-58
	[D] Withholding Action .....	13-58
	[E] Notices of Intended Enforcement Action .....	13-59
	[F] Appeals .....	13-59
	[G] Withdrawal of Inspection.....	13-59
§ 13:6.5	Civil and Criminal Actions .....	13-60
§ 13:6.6	Notice of Warning.....	13-60
§ 13:6.7	Imports .....	13-60
§ 13:7	Other Federal Agencies Regulating Food .....	13-61
§ 13:7.1	Generally .....	13-61
§ 13:7.2	Alcohol and Tobacco Tax and Trade Bureau .....	13-61
§ 13:8	States.....	13-64
§ 13:8.1	Food Other Than Meat and Poultry .....	13-64
	[A] Generally .....	13-64
	[B] Federal-State Cooperative Programs.....	13-64
§ 13:8.2	Meat and Poultry .....	13-66
§ 13:9	Private Actions .....	13-66

## **Chapter 14 Tobacco Products**

*David B. Clissold, Sara W. Koblitz & Faraz R. Siddiqui*

§ 14:1	Overview .....	14-2
§ 14:2	Scope of Authority .....	14-2
§ 14:3	Prohibited Adulteration and Misbranding.....	14-4
§ 14:4	Tobacco Product Scientific Advisory Committee.....	14-6
§ 14:5	Establishment of Tobacco Product Standards.....	14-7
§ 14:6	Premarket Authorities for New Tobacco Products .....	14-8
§ 14:6.1	Generally .....	14-8
§ 14:6.2	Premarket Notifications.....	14-9
§ 14:6.3	Premarket Applications.....	14-11
	[A] Generally .....	14-11
	[B] PMTA Marketing Orders and Denials .....	14-11
	[C] Withdrawal and Suspension of an Authorized Product .....	14-13

*Table of Contents*

§ 14:7	Modified Risk Tobacco Products .....	14-13
§ 14:8	Reporting Requirements .....	14-15
§ 14:8.1	Registration and Listing .....	14-15
§ 14:8.2	Health Information and Health Effects .....	14-15
§ 14:8.3	“Track-and-Trace” Requirements.....	14-16
§ 14:9	Restrictions on the Sale, Distribution, Advertising, and Promotion of Tobacco Products.....	14-17
§ 14:10	Final Deeming Rule .....	14-22
§ 14:11	Other Challenges to the Tobacco Control Act and Deeming Rule .....	14-24
§ 14:12	Enforcement .....	14-28
§ 14:12.1	State and Federal-State Enforcement Efforts.....	14-28
§ 14:12.2	State Enforcement Efforts: Electronic Cigarettes .....	14-30
§ 14:12.3	FDA Enforcement Efforts.....	14-31
§ 14:12.4	Warning Letters.....	14-31
§ 14:12.5	Civil Money Penalty Actions.....	14-32
§ 14:12.6	No Tobacco Sales Order .....	14-33
§ 14:13	FDA’s Comprehensive Plan for Tobacco and Nicotine Regulation.....	14-34

**Chapter 15 Animal Products**

*Diane B. McColl, Karla L. Palmer, A. Wes Siegner, Jr.,  
David B. Clissold, Riëtte van Laack & Ricardo Carvajal*

§ 15:1	Overview .....	15-2
§ 15:2	Authority and Organization.....	15-3
§ 15:3	New Animal Drugs.....	15-4
§ 15:3.1	Premarket Authorities.....	15-4
§ 15:3.2	Investigational Use .....	15-5
§ 15:3.3	Product Review and Approval.....	15-6
§ 15:3.4	Postmarket Authorities .....	15-7
[A]	Generally .....	15-7
[B]	Reporting Requirements .....	15-7
[C]	Changes to an Application.....	15-8
[D]	Withdrawal .....	15-9
§ 15:3.5	Medicated Animal Feed .....	15-9
§ 15:4	Animal Food and Animal Feed .....	15-10
§ 15:4.1	Generally .....	15-10
§ 15:4.2	Premarket Authorities.....	15-12
§ 15:4.3	Food Additive Petitions .....	15-12
§ 15:4.4	GRAS Ingredients .....	15-13
§ 15:4.5	AAFCO Feed Ingredient Definitions .....	15-14

§ 15:5	Animal Supplements .....	15-15
§ 15:5.1	Regulatory Framework .....	15-15
§ 15:5.2	National Animal Supplement Council.....	15-16
§ 15:6	Other Product Types .....	15-17
§ 15:6.1	Veterinary Devices .....	15-17
§ 15:6.2	Veterinary Biologics .....	15-18
§ 15:6.3	Pesticides .....	15-20
§ 15:6.4	Combination Products.....	15-20
§ 15:6.5	Genetically Engineered Animals .....	15-21
§ 15:6.6	Animal Stem-Cell-Based Products .....	15-22
§ 15:7	Animal Drug Compounding.....	15-23
§ 15:7.1	Generally .....	15-23
§ 15:8	Other Use Outside the Scope of an Approval.....	15-24
§ 15:8.1	Generally .....	15-24
§ 15:8.2	Off-Label and Extra-Label Use .....	15-26
§ 15:8.3	Indexing and Conditional Approval .....	15-26
§ 15:8.4	Regulatory Enforcement Discretion .....	15-28
§ 15:9	Coordination with Other Government Actors .....	15-29
§ 15:9.1	Other FDA Centers.....	15-29
§ 15:9.2	U.S. Department of Agriculture—Center for Veterinary Biologics .....	15-29
§ 15:9.3	EPA.....	15-30
§ 15:9.4	State Regulators .....	15-30
§ 15:10	Enforcement .....	15-30
§ 15:10.1	Generally .....	15-30
§ 15:10.2	Court Action.....	15-31
§ 15:10.3	Warning Letters.....	15-31

## **Chapter 16   Cosmetics**

*Etan J. Yeshua & Ricardo Carvajal*

§ 16:1	Overview .....	16-2
§ 16:2	Definition of “Cosmetic” .....	16-3
§ 16:3	Statutory and Regulatory Framework.....	16-4
§ 16:4	Adulteration .....	16-4
§ 16:4.1	Adulteration and Cosmetic Ingredients.....	16-5
[A]	FDA Regulation of Cosmetic Ingredients.....	16-5
[B]	Industry Self-Regulation of Cosmetic Ingredients.....	16-6
§ 16:4.2	Color Additives .....	16-7
[A]	Color Additives Generally.....	16-7
[B]	The Delaney Clause .....	16-8
[C]	Coal-Tar Hair Dye Exemption .....	16-9
[D]	Tattoos.....	16-9

*Table of Contents*

§ 16:4.3	Adulteration and Cosmetic Manufacturing.....	16-10
[A]	Cosmetic GMP Guidance Documents.....	16-10
[B]	Voluntary Cosmetic Registration Program .....	16-11
§ 16:5	Misbranding .....	16-12
§ 16:5.1	Mandatory Label Statements .....	16-13
[A]	Label Versus Labeling.....	16-13
[B]	Requirements Under the Fair Packaging and Labeling Act.....	16-14
[C]	Warnings.....	16-16
§ 16:5.2	Claims .....	16-16
[A]	Cosmetic Claims Versus Drug Claims.....	16-16
[B]	Other Claims.....	16-18
[C]	Claim Substantiation.....	16-19
§ 16:6	FDA Enforcement of Cosmetic Requirements .....	16-20
§ 16:6.1	Inspections .....	16-20
§ 16:6.2	Warning Letters.....	16-21
§ 16:6.3	Additional Enforcement Actions .....	16-22
§ 16:7	Other Sources of Legal and Regulatory Challenges .....	16-22

**Chapter 17   Controlled Substances**

*John A. Gilbert, Jr. & Larry K. Houck*

§ 17:1	Overview .....	17-2
§ 17:2	Scope of Enforcement .....	17-3
§ 17:2.1	Classification of Controlled Substances .....	17-4
§ 17:2.2	Facility and Practitioner Registration .....	17-4
§ 17:2.3	Security for Storage and Handling.....	17-5
§ 17:2.4	Complete and Accurate Records.....	17-6
§ 17:2.5	Form, Manner, and Content of Prescriptions .....	17-7
§ 17:2.6	Transaction and Ad Hoc Reporting .....	17-8
§ 17:3	Type of Enforcement.....	17-10
§ 17:3.1	Administrative Enforcement Actions .....	17-10
[A]	Verbal Warning .....	17-11
[B]	Letter of Admonition .....	17-11
[C]	Voluntary Surrender.....	17-11
[D]	Informal Administrative Hearing.....	17-12
[E]	Order to Show Cause.....	17-12
[F]	Immediate Suspension.....	17-14
§ 17:3.2	Civil Penalties.....	17-15
§ 17:3.3	Criminal and Forfeiture Enforcement Actions.....	17-16
§ 17:4	Examples of Enforcement Cases .....	17-17
§ 17:4.1	Administrative Revocation of Prescriber and Practitioner Registration .....	17-17
§ 17:4.2	Failure to Maintain Complete and Accurate Records .....	17-19

§ 17:4.3	Dispensing for Non-Legitimate Purpose .....	17-21
§ 17:4.4	Failure to Report Suspicious Orders .....	17-25
§ 17:4.5	National Prescription Opioid Litigation .....	17-32
§ 17:4.6	State Prescription Opioid Litigation .....	17-32
§ 17:4.7	Cases Involving List I Chemicals .....	17-34
§ 17:4.8	Enforcement Action Against Non-Registrants .....	17-35
§ 17:5	Conclusion .....	17-36

## **Chapter 18 Promotion and Marketing of Prescription Drugs, Biologics, and Devices**

*Dara Katcher Levy, Jeffrey N. Wasserstein & Sara W. Koblitz*

§ 18:1	Overview .....	18-2
§ 18:2	Legal Overview .....	18-3
§ 18:2.1	Prohibited Acts .....	18-3
[A]	Generally .....	18-3
[B]	Misbranding .....	18-4
[C]	Unapproved New Drug.....	18-4
§ 18:2.2	Classes of Promotional Materials.....	18-5
[A]	Generally .....	18-5
[B]	Promotional Labeling.....	18-5
[C]	Advertising .....	18-6
§ 18:3	Promotional Requirements .....	18-7
§ 18:3.1	Generally .....	18-7
§ 18:3.2	Substantiation of Claims .....	18-7
[A]	Generally .....	18-7
[B]	Comparative Claims.....	18-9
[C]	Implied Claims .....	18-10
[D]	Pharmacoeconomic Claims .....	18-11
§ 18:3.3	Fair Balance and Contextualizing Information.....	18-13
§ 18:3.4	Submission of Promotional Materials .....	18-14
§ 18:4	Types of Promotion.....	18-14
§ 18:4.1	Pre-Approval Promotion.....	18-14
§ 18:4.2	Post-Approval Promotion.....	18-16
[A]	Generally .....	18-16
[B]	Advertising to Consumers—Specific Requirements.....	18-17
[C]	Reminder Materials .....	18-19
§ 18:4.3	Excluded Types of Communications .....	18-20
[A]	Generally .....	18-20
[B]	Continuing Medical Education (CME) Programs.....	18-20



*Table of Contents*

[C]	Scientific Exchange .....	18-20
[D]	Disease Awareness Communications .....	18-24
§ 18:5	Internet and Social Media.....	18-26
§ 18:5.1	Generally .....	18-26
§ 18:5.2	Postmarketing Submission of Promotional Materials.....	18-27
§ 18:5.3	Character and Space Limitations .....	18-28
§ 18:5.4	Correcting Third-Party Misinformation.....	18-28
§ 18:5.5	Additional Issues Related to Internet and Social Media .....	18-29
§ 18:6	Devices .....	18-29
§ 18:6.1	Generally .....	18-29
§ 18:6.2	Device Labeling.....	18-30
§ 18:6.3	Device Advertising .....	18-32
§ 18:6.4	Device Substantiation .....	18-32
§ 18:6.5	Unapproved Device Promotion .....	18-34
§ 18:6.6	Applicable FDA Guidance Documents.....	18-34
Appendix 18A	FDA Organizations and Areas of Responsibilities .....	App. 18A-1

**Chapter 19 Health Care Fraud and Abuse Laws**

*Alan M. Kirschenbaum & Serra J. Schlanger*

§ 19:1	Overview .....	19-3
§ 19:2	Federal Health Care Program Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)).....	19-4
§ 19:2.1	Prohibited Conduct.....	19-4
§ 19:2.2	Statutory Exemptions .....	19-6
§ 19:2.3	AKS Safe Harbor Regulations .....	19-8
[A]	General Considerations .....	19-8
[B]	Discounts (42 C.F.R. § 1001.952(h)).....	19-8
[C]	Personal Services and Management Contracts (42 C.F.R. § 1001.952(d)).....	19-13
[D]	Group Purchasing Organizations (42 C.F.R. § 1001.952(j)).....	19-14
[E]	Employees (42 C.F.R. § 1001.952(i)) .....	19-15
[F]	Price Reductions to Eligible Managed Care Organizations (42 C.F.R. § 1001.952(t)) .....	19-15
[G]	Cost-Sharing Waivers by Pharmacies (42 C.F.R. § 1001.952(k)).....	19-16
[H]	Medicare Coverage Gap Discount Program (42 C.F.R. § 1001.952(aa)) .....	19-17
[I]	Other Safe Harbors .....	19-17

§ 19:2.4	OIG Guidance on Compliance with the AKS.....	19-18
[A]	Special Fraud Alert.....	19-18
[B]	OIG Compliance Program Guidance .....	19-18
[C]	OIG Advisory Opinions .....	19-19
§ 19:3	Other Anti-Kickback and Related Laws and Industry Codes .....	19-20
§ 19:3.1	Civil Monetary Penalty for Remuneration to Medicare or Medicaid Beneficiary (42 U.S.C. § 1320a-7a(a)(5), (i)(6)) .....	19-20
§ 19:3.2	Anti-Kickback Act of 1986 (41 U.S.C. §§ 8701–8707) .....	19-21
§ 19:3.3	Stark Anti-Referral Law (42 U.S.C. § 1395nn).....	19-22
§ 19:3.4	State Anti-Kickback Laws .....	19-22
§ 19:3.5	Federal Payment Transparency Reporting Law (Physician Payments Sunshine Act) .....	19-23
§ 19:3.6	State Gift Prohibitions and Transparency Reporting Laws .....	19-25
§ 19:3.7	State Compliance Program Requirements.....	19-25
§ 19:3.8	State Consumer Protection Laws .....	19-26
§ 19:3.9	State Laws Regulating Professional Conduct of Physicians and Pharmacists.....	19-26
§ 19:3.10	PhRMA Code.....	19-26
§ 19:3.11	AdvaMed Code .....	19-27
§ 19:3.12	Health Care Fraud (18 U.S.C. § 1347).....	19-29
§ 19:4	Enforcement Risk Areas for Drug and Device Companies Under the AKS.....	19-30
§ 19:4.1	Free Goods, Services, and Other Benefits.....	19-30
[A]	Free Goods.....	19-30
[A][1]	Generally.....	19-30
[A][2]	OIG Guidance.....	19-30
[A][3]	Enforcement.....	19-32
[A][3][a]	Free Product .....	19-32
[A][3][b]	Gifts and Travel.....	19-33
[B]	Reimbursement Assistance and Other Free Services.....	19-34
[C]	Patient Assistance Programs .....	19-35
[C][1]	OIG Guidance.....	19-35
[C][2]	Enforcement.....	19-36
[D]	Coupons .....	19-38
[D][1]	Generally.....	19-38
[D][2]	OIG Position .....	19-39
[D][3]	Enforcement.....	19-39
[E]	Practice Tips .....	19-40
§ 19:4.2	Bundled Discounts and “Swapping”.....	19-41
[A]	Generally .....	19-41

*Table of Contents*

	[B]	OIG Guidance .....	19-42
	[C]	Enforcement .....	19-43
	[D]	Practice Tips .....	19-44
§ 19:4.3		Consulting Fees .....	19-44
	[A]	Generally .....	19-44
	[B]	OIG Guidance .....	19-44
	[C]	Enforcement .....	19-45
	[D]	Practice Tips .....	19-46
§ 19:4.4		Grants .....	19-47
	[A]	Generally .....	19-47
	[B]	OIG Guidance .....	19-47
	[C]	Enforcement .....	19-48
	[D]	Practice Tips .....	19-48
	[D][1]	Grants for Research .....	19-48
	[D][2]	Grants to Support Independent Scientific or Educational Programs .....	19-49
§ 19:4.5		Postmarketing Studies and Registries .....	19-49
	[A]	OIG Guidance .....	19-49
	[B]	Enforcement .....	19-50
	[C]	Practice Tips .....	19-51
	[C][1]	Postmarketing Studies .....	19-51
	[C][2]	Registries .....	19-52
§ 19:4.6		Payments to Pharmacies .....	19-52
	[A]	Generally .....	19-52
	[B]	OIG Guidance .....	19-53
	[C]	Enforcement .....	19-53
	[D]	Practice Tips .....	19-54
§ 19:5		Federal False Claims Act (31 U.S.C. §§ 3729–3733) .....	19-54
	§ 19:5.1	Generally .....	19-54
	§ 19:5.2	FCA Prohibitions .....	19-55
	§ 19:5.3	FCA Liability for Kickbacks .....	19-56
	§ 19:5.4	Liability for Providing Reimbursement Advice .....	19-56
		[A] Generally .....	19-56
		[B] OIG Guidance .....	19-56
		[C] Enforcement .....	19-57
	§ 19:5.5	Inflation of Reported Drug Prices .....	19-57
	§ 19:5.6	Reporting of Prices to CMS .....	19-59
		[A] Generally .....	19-59
		[B] OIG Guidance .....	19-59
		[C] Enforcement .....	19-59
	§ 19:5.7	Off-Label Promotion As a Basis for FCA Liability .....	19-60
	§ 19:5.8	Other FDC Act Violations As a Basis for FCA Allegations .....	19-62

**Chapter 20 Internal Investigations**

*Anne K. Walsh & Andrew J. Hull*

§ 20:1 Overview ..... 20-3

§ 20:2 Triggers of an Investigation..... 20-4

    § 20:2.1 Laying the Foundation ..... 20-4

    § 20:2.2 Sources of Information about Investigable Situations ..... 20-5

        [A] Employees..... 20-5

        [B] Victims ..... 20-6

        [C] Whistleblowers ..... 20-6

        [D] Government Agencies..... 20-6

        [E] Other Third-Party Sources ..... 20-7

        [F] Compliance Hotlines ..... 20-8

    § 20:2.3 Documenting the Complaint ..... 20-9

    § 20:2.4 Public Statements ..... 20-9

§ 20:3 Initiating an Investigation ..... 20-10

    § 20:3.1 Generally ..... 20-10

Table 20-1 Cost/Benefit Analysis of Initiating Formal Versus Informal Internal Investigation ..... 20-12

    § 20:3.2 Timeliness ..... 20-13

    § 20:3.3 Prevention of Retaliatory Claims ..... 20-13

    § 20:3.4 Stopping Ongoing Conduct..... 20-13

§ 20:4 Scope of the Investigation ..... 20-14

    § 20:4.1 Identifying Goals ..... 20-14

    § 20:4.2 Creating a Plan ..... 20-14

§ 20:5 Staffing the Investigation..... 20-15

    § 20:5.1 Generally ..... 20-15

    § 20:5.2 Legal Counsel ..... 20-15

        [A] Generally ..... 20-15

        [B] Internal Versus External Counsel ..... 20-15

        [C] Separate Counsel for Employees and Others..... 20-17

        [D] Privilege Issues ..... 20-19

    § 20:5.3 Investigations by Non-Legal Company Personnel ..... 20-20

    § 20:5.4 Use of Outside Experts ..... 20-21

    § 20:5.5 Oversight of the Investigation..... 20-21

§ 20:6 Conducting the Investigation ..... 20-22

    § 20:6.1 Generally ..... 20-22

    § 20:6.2 Documents ..... 20-22

        [A] Document Preservation ..... 20-22

            [A][1] Custodians ..... 20-22

            [A][2] Information Technology ..... 20-22

            [A][3] Litigation Hold Notices ..... 20-23

Table of Contents

[B]	Document Collection .....	20-23
[B][1]	Generally.....	20-23
[B][2]	Custodian Interviews .....	20-23
[B][3]	Paper Documents .....	20-24
[B][4]	Electronic Files .....	20-24
[C]	Role of IT Experts .....	20-24
[D]	Document Management and Review .....	20-25
§ 20:6.3	Interviews .....	20-26
[A]	Generally .....	20-26
[B]	Preparation .....	20-26
[B][1]	Generally.....	20-26
[B][2]	Selection of Interviewees .....	20-26
[B][3]	Sequence of Interviews .....	20-27
[B][4]	Scheduling Interviews .....	20-28
[B][5]	Interview Outline and Questions .....	20-29
[B][6]	Providing Documents to Interviewees .....	20-29
[C]	Conducting Interviews.....	20-29
[C][1]	Interviewers.....	20-29
[C][2]	Tone .....	20-30
[C][3]	<i>Upjohn</i> Warnings and Other Preliminary Statements .....	20-30
[C][4]	Asking Questions .....	20-31
[C][5]	Concluding Instructions.....	20-32
[D]	Interviews of Third Parties.....	20-32
[E]	Other Investigative Techniques.....	20-32
§ 20:7	Investigation Records.....	20-33
§ 20:7.1	Generally .....	20-33
§ 20:7.2	Document Summaries .....	20-33
§ 20:7.3	Interview Reports.....	20-33
§ 20:7.4	Reports of Findings .....	20-34
[A]	Interim Updates .....	20-34
[B]	Final Report .....	20-34
§ 20:8	Remedial Actions.....	20-36
§ 20:8.1	Stopping Violative Conduct .....	20-36
§ 20:8.2	Discipline .....	20-36
[A]	Generally .....	20-36
[B]	Verbal Warnings.....	20-36
[C]	Written Warnings.....	20-37
[D]	Training.....	20-37
[E]	Termination.....	20-37
[F]	Severance Agreements .....	20-37
§ 20:8.3	Adopting New Policies and Controls.....	20-38
§ 20:8.4	Self-Disclosure .....	20-38

§ 20:9	Special Considerations for International Investigations .....	20-41
Appendix 20A	Internal Investigation and Litigation	
	Hold Notice .....	App. 20A-1
Appendix 20B	Sample <i>Upjohn</i> Warning.....	App. 20B-1

## **Chapter 21   FDA Inspections**

*Douglas B. Farquhar, Karla L. Palmer & Mark I. Schwartz*

§ 21:1	Role of Inspections .....	21-2
§ 21:1.1	Overview.....	21-2
§ 21:1.2	FDA's Reasons to Inspect.....	21-4
§ 21:1.3	Potential Outcomes of Inspections.....	21-5
§ 21:2	FDA's Authority to Access Facilities and Records, and Conduct Interviews .....	21-6
§ 21:2.1	Generally .....	21-6
§ 21:2.2	Authority with Respect to Specific Facilities.....	21-7
[A]	Food and Dietary Supplement Facilities.....	21-7
[B]	Drug and Biologic Facilities .....	21-8
[C]	Device Facilities.....	21-10
[D]	Cosmetic Facilities.....	21-11
[E]	Foreign Facilities .....	21-11
[F]	Pharmacies .....	21-11
§ 21:2.3	Who Conducts an Inspection? .....	21-12
§ 21:2.4	FDA Credentials and Forms .....	21-13
§ 21:2.5	Refusal or Delay, the Definition and Consequences .....	21-14
§ 21:2.6	Involvement of State and Local Officials in Inspections .....	21-15
§ 21:3	Preparing for an Inspection.....	21-15
§ 21:3.1	Generally .....	21-15
§ 21:3.2	Policies.....	21-16
§ 21:3.3	Personnel .....	21-17
§ 21:3.4	Practice, Practice, Practice.....	21-17
§ 21:4	During an Inspection.....	21-18
§ 21:4.1	Generally .....	21-18
§ 21:4.2	Questions and Answers .....	21-19
§ 21:4.3	Keeping a Record.....	21-19
§ 21:4.4	Close-Out Meetings.....	21-19
§ 21:5	Post-Inspection Follow-Up.....	21-20
§ 21:5.1	Form 483 Response.....	21-20
[A]	Generally .....	21-20
[B]	Timeline .....	21-21

Table of Contents

[C]	How to Address and Format Your Response.....	21-21
[D]	Tips for Success .....	21-22
§ 21:5.2	Close Out and the Establishment Inspection Report .....	21-23
§ 21:5.3	Publicity.....	21-23
§ 21:5.4	Warning Letter Response.....	21-24
[A]	Generally .....	21-24
[B]	Timeline .....	21-24
[C]	How to Address and Format Your Response.....	21-25
[D]	Tips for Success .....	21-25

**Chapter 22 Issues Arising from Criminal Cases**

*James P. Ellison*

§ 22:1	Overview .....	22-2
§ 22:2	How Does a Criminal Investigation Commence?.....	22-3
§ 22:2.1	Generally .....	22-3
§ 22:2.2	Agencies That Investigate and Prosecute FDA Criminal Matters .....	22-3
[A]	Criminal Investigators .....	22-3
[A][1]	FDA Office of Criminal Investigations .....	22-3
[A][2]	Federal Bureau of Investigation .....	22-6
[A][3]	U.S. Department of Health and Human Services Office of Inspector General .....	22-7
[A][4]	Others .....	22-7
[B]	Criminal Prosecutors .....	22-7
§ 22:2.3	Regulatory Referrals .....	22-7
§ 22:2.4	Consumer Complaints and Public Health Issues.....	22-8
§ 22:2.5	Whistleblowers, the False Claims Act, and <i>Qui Tams</i> .....	22-8
§ 22:3	Parallel Investigations—Government Sharing of Information .....	22-9
§ 22:4	Indications That There May Be a Criminal Investigation.....	22-9
§ 22:4.1	Generally .....	22-9
§ 22:4.2	Document Requests.....	22-10
[A]	Grand Jury Subpoenas .....	22-10
[B]	HIPAA Subpoenas.....	22-11
[C]	Other Administrative Subpoenas .....	22-11
[D]	Privilege Issues, Self-Incrimination, and Immunity .....	22-12
[D][1]	Attorney-Client Privilege .....	22-12
[D][2]	Attorney Work Product Protection.....	22-12

[D][3] Fifth Amendment Privilege Against  
Self-Incrimination ..... 22-14

§ 22:4.3 Testimonial Subpoenas ..... 22-16

    [A] Generally ..... 22-16

    [B] Grand Jury Secrecy ..... 22-16

        [B][1] Generally ..... 22-16

        [B][2] Government Obligations ..... 22-17

        [B][3] No Obligations on Other Persons ..... 22-17

§ 22:4.4 Interviews ..... 22-18

    [A] Generally ..... 22-18

    [B] Represented Parties and Persons ..... 22-19

        [B][1] Current Employees ..... 22-19

        [B][2] Former Employees ..... 22-20

    [C] Restrictions on the Government ..... 22-20

    [D] Ethical Issues for Company Counsel and  
    *Upjohn* Warnings ..... 22-21

    [E] Joint Defense Agreements ..... 22-23

§ 22:4.5 Search Warrants ..... 22-24

    [A] Generally ..... 22-24

    [B] General Requirements in Issuing and  
    Serving a Search Warrant ..... 22-24

    [C] Practical Considerations ..... 22-26

§ 22:5 Influencing the Criminal Investigation ..... 22-26

    § 22:5.1 Voluntary Disclosure ..... 22-26

    § 22:5.2 Proffer Sessions and Government  
    Presentations ..... 22-27

§ 22:6 Plea Negotiations ..... 22-28

    § 22:6.1 Generally ..... 22-28

    § 22:6.2 Sentencing Guidelines—Organizational  
    Guidelines ..... 22-28

        [A] Compliance Programs ..... 22-28

    § 22:6.3 Non-Prosecution and Deferred Prosecution  
    Agreements ..... 22-29

    § 22:6.4 Collateral Consequences—Exclusion and  
    Debarment ..... 22-30

§ 22:7 Select Constitutional Defenses ..... 22-31

    § 22:7.1 First Amendment ..... 22-31

    § 22:7.2 Fifth Amendment Due Process  
    (Clarity of the Law) ..... 22-33

**Table of Authorities** ..... T-1

**Index** ..... I-1